Details of the Drug Combination

General Information of Drug Combination (ID: DC3OYDW)

Drug Combination Name
Sotrastaurin acetate Alpelisib
Indication
Disease Entry Status REF
Uveal Melanoma Phase 1 [1]
Component Drugs Sotrastaurin acetate   DME53YS Alpelisib   DMEXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sotrastaurin acetate
Disease Entry ICD 11 Status REF
Renal transplantation NE84 Phase 2 [2]
Sotrastaurin acetate Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protein kinase C alpha (PRKCA) TTFJ8Q1 KPCA_HUMAN Inhibitor [2]
Protein kinase C theta (PRKCQ) TT8QL1J KPCT_HUMAN Inhibitor [2]
Protein kinase C beta (PRKCB) TTYPXQF KPCB_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Alpelisib
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Alpelisib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase alpha (PIK3CA) TTEUNMR PK3CA_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Alpelisib Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02273219) Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
2 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7955).
5 Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907.